REG - hVIVO PLC - Annual Report & Notice of AGM

hVIVOAnnouncement

15/04/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240415:nRSO5044Ka&default-theme=true

RNS Number : 5044K  hVIVO PLC  15 April 2024

hVIVO plc

("hVIVO" or the "Company")

 

Annual Report & Notice of AGM

 

hVIVO plc (AIM & Euronext: HVO), a rapidly growing specialist contract
research organisation (CRO) and world leader in testing infectious and
respiratory disease products using human challenge clinical trials, confirms
that the Company's Annual Report and Accounts for the year ended 31 December
2023 and the Notice of Annual General Meeting ("AGM") will be posted to
shareholders today.

 

The 2023 Annual Report and Accounts, the Notice of AGM and accompanying form
of proxy are available to download from the Company's website www.hvivo.com
(http://www.hvivo.com) .

 

The Annual General Meeting will be held at the offices of DAC Beachcroft LLP,
25 Walbrook, London EC4N 8AF, United Kingdom on 13 May 2024 at 11am (BST).

 

For further information please contact:

 

 hVIVO plc                                       +44 (0) 20 7756 1300
 Yamin 'Mo' Khan, Chief Executive Officer

 Stephen Pinkerton, Chief Financial Officer

 Cavendish Capital Markets Limited (Nominated Adviser and Joint Broker)                  +44 (0) 20 7220 0500
 Geoff Nash, Charlie Beeson, Nigel Birks, Harriet Ward

 Peel Hunt LLP (Joint Broker)                                        +44 (0)20 7418 8900
 James Steel, Dr Christopher Golden

 Davy (Euronext Growth Adviser and Joint Broker)                     +353 (0) 1 679 6363
 Anthony Farrell, Niall Gilchrist

 Walbrook PR (Financial PR & IR)                 +44 (0) 20 7933 8780 or hvivo@walbrookpr.com

 Stephanie Cuthbert / Phillip Marriage /         +44 (0) 7796 794 663 / +44 (0) 7867 984 082 /

Louis Ashe-Jepson
+44 (0) 7747 515 393

 

 

Notes to Editors

 

About hVIVO

 

hVIVO plc (http://www.hvivo.com) (ticker: HVO) (formerly Open Orphan plc) is
a rapidly growing specialist contract research organisation (CRO) and the
world leader in testing infectious and respiratory disease vaccines and
therapeutics using human challenge clinical trials. The Group provides
end-to-end early clinical development services to its large, established and
growing repeat client base, which includes four of the top 10 largest global
biopharma companies.

 

The Group's fast-growing services business includes a unique portfolio of 11
human challenge models, with a number of new models under development, to test
a broad range of infectious and respiratory disease products. The Group has
world class challenge agent manufacturing capabilities, specialist drug
development and clinical consultancy services via its Venn Life Sciences
brand, and a lab offering via its hLAB brand, which includes virology,
immunology biomarker and molecular testing. The Group offers additional
clinical field trial services such as patient recruitment and clinical trial
site services.

 

hVIVO runs challenge trials in London - its new state-of-the-art facilities
opening in Canary Wharf in 2024 is set to be the world's largest commercial
human challenge trial unit, with highly specialised on-site virology and
immunology laboratories, and an outpatient unit. To recruit volunteers /
patients for its studies, the Group leverages its unique clinical trial
recruitment capability via its FluCamp (http://www.flucamp.com/) volunteer
screening facilities in London and Manchester.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ACSEASLAFFNLEFA